Jason A. Leverone insider trades: OnKure Therapeutics (OKUR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | OKUR | ↓ Sell | 302 | $2.97 | $898 | Direct | Sep 23, 2026 (2d) |
| Jun 22, 2026 | OKUR | ↓ Sell | 303 | $4.40 | $1K | Direct | Jun 24, 2026 (2d) |
| Mar 23, 2026 | OKUR | ↓ Sell | 301 | $4.16 | $1K | Direct | Mar 24, 2026 (1d) |
| Dec 22, 2025 | OKUR | ↓ Sell | 302 | $2.97 | $896 | Direct | Dec 23, 2025 (1d) |
| Sep 22, 2025 | OKUR | ↓ Sell | 303 | $2.62 | $795 | Direct | Sep 24, 2025 (2d) |
| Jun 23, 2025 | OKUR | ↓ Sell | 303 | $2.38 | $722 | Direct | Jun 25, 2025 (2d) |
| Apr 7, 2025 | OKUR | ↓ Sell | 3,122 | $2.94 | $9K | Direct | Apr 8, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OKUR insiders
Open-market trades in the last 12 months
About Jason A. Leverone's insider trades
Jason A. Leverone is Chief Financial Officer at OnKure Therapeutics (OKUR). Since Apr 7, 2025, Jason has reported no open-market purchases and 7 sales worth $15K on SEC Form 4. In the last 12 months: 4 sales ($4K).
Their filings also include grants and awards (9 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OKUR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.